Cargando…

Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients

Clinical resistance to chemotherapy is one of the major problems in breast cancer treatment. In this study we analyzed possible impact of 22 polymorphic variants on the treatment response in 324 breast cancer patients. Selected genes were involved in FAC chemotherapy drugs transport (ABCB1, ABCC2, A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tecza, Karolina, Pamula-Pilat, Jolanta, Lanuszewska, Joanna, Grzybowska, Ewa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341838/ https://www.ncbi.nlm.nih.gov/pubmed/27527855 http://dx.doi.org/10.18632/oncotarget.11053

Ejemplares similares

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Pharmacogenetics of FAC chemotherapy side effects in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms, efficiency and toxicity of cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients
por: Pamuła-Piłat, Jolanta, et al.
Publicado: (2020)

High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk
por: Wagner, Kerstin, et al.
Publicado: (2007)

Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes
por: Budryk, M, et al.
Publicado: (2012)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age
por: Huszno, Joanna, et al.
Publicado: (2020)

Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland
por: Pamuła, Jolanta, et al.
Publicado: (2006)

Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
por: Pereira-Oliveira, Maria, et al.
Publicado: (2019)

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
por: O'Byrne, K. J., et al.
Publicado: (1998)

Fluorouracil Catabolism in the Combination Treatment of Cyclophosphamide, Methotrexate and Fluorouracil
por: De Bruijn, Ernst A., et al.
Publicado: (1992)

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
por: Ferguson, J. E., et al.
Publicado: (1993)

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
por: Yeo, Winnie, et al.
Publicado: (2022)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
por: Gabra, H., et al.
Publicado: (1996)

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
por: Pierga, J. Y., et al.
Publicado: (1998)

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
por: van der Wall, E., et al.
Publicado: (1996)

Prevalence of the most frequent BRCA1 mutations in Polish population
por: Brozek, Izabela, et al.
Publicado: (2011)

Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study
por: Rau, Kun-Ming, et al.
Publicado: (2015)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
por: Cebon, J. S., et al.
Publicado: (1990)

Rare Case of Reversible Pulmonary Arterial Hypertension Secondary to Cyclophosphamide and Doxorubicin Chemotherapy
por: Javed, Aneeqa, et al.
Publicado: (2022)

Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study
por: Lisowska, Katarzyna Marta, et al.
Publicado: (2014)

Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis
por: Liu, Shuyu, et al.
Publicado: (2021)

Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2020)

Global and Regional Longitudinal Strain Reduction in Breast Cancer Patients After First Chemotherapy Cycle With Fluorouracil, Adriamycin, and Cyclophosphamide Regimen
por: Astuti, Astri, et al.
Publicado: (2021)

Increasing pacemaker lead impedance and pacing threshold after initiation of chemotherapy with doxorubicin and cyclophosphamide
por: Varela, Daniel L., et al.
Publicado: (2022)

A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients
por: Wu, Lina, et al.
Publicado: (2015)

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
por: Adeel, Muhammad, et al.
Publicado: (2019)

Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report
por: Dudaladava, Volha, et al.
Publicado: (2006)

The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients
por: Szafron, Lukasz Michal, et al.
Publicado: (2015)

Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
por: Kim, Chang Gon, et al.
Publicado: (2016)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
por: Chen, Yanhua, et al.
Publicado: (2020)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study
por: Shizuku, Masato, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_olvqc7fd7vke49dghi3hl1t1n6